Floatz logo

(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE

Depressive Disorder

VA Office of Research and DevelopmentSmall moleculePhase 4 / ApprovedActive
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
74/ 100
Competitive Position
73/ 100

Competitive context

77 Active assets in the Depressive Disorder cohort.

Asset / SponsorPhaseRating
Brexpiprazole
Dr. Albert Kar-Kin Chung
Phase 4A
Saredutant
Sanofi
Phase 3BBB
Jnj-54135419
Chinese PLA General Hospital
Phase 4BBB
Paroxetine
Brigham and Women's Hospital
Phase 4BBB
CITALOPRAM
Western University, Canada
Phase 4BBB

View all 50 →

Same molecule, other indications

(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE is also rated in:

chronic pain syndromeActive
BBB
Indicative · Phase 4
74 / 100
View asset →
post-traumatic stress disorderActive
BBB
Indicative · Phase 4
74 / 100
View asset →
neuralgiaActive
BBB
Indicative · Phase 4
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →